EconPapers    
Economics at your fingertips  
 

The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation

Michael J. Capper, Gareth S. A. Wright, Letizia Barbieri, Enrico Luchinat, Eleonora Mercatelli, Luke McAlary, Justin J. Yerbury, Paul M. O’Neill, Svetlana V. Antonyuk, Lucia Banci () and S. Samar Hasnain ()
Additional contact information
Michael J. Capper: University of Liverpool
Gareth S. A. Wright: University of Liverpool
Letizia Barbieri: University of Florence
Enrico Luchinat: University of Florence
Eleonora Mercatelli: University of Florence
Luke McAlary: University of Wollongong
Justin J. Yerbury: University of Wollongong
Paul M. O’Neill: University of Liverpool
Svetlana V. Antonyuk: University of Liverpool
Lucia Banci: University of Florence
S. Samar Hasnain: University of Liverpool

Nature Communications, 2018, vol. 9, issue 1, 1-9

Abstract: Abstract Superoxide dismutase-1 (SOD1) mutants, including those with unaltered enzymatic activity, are known to cause amyotrophic lateral sclerosis (ALS). Several destabilizing factors contribute to pathogenicity including a reduced ability to complete the normal maturation process which comprises folding, metal cofactor acquisition, intra-subunit disulphide bond formation and dimerization. Immature SOD1 forms toxic oligomers and characteristic large insoluble aggregates within motor system cells. Here we report that the cysteine-reactive molecule ebselen efficiently confers the SOD1 intra-subunit disulphide and directs correct SOD1 folding, depopulating the globally unfolded precursor associated with aggregation and toxicity. Assisted formation of the unusual SOD1 cytosolic disulphide bond could have potential therapeutic applications. In less reducing environments, ebselen forms a selenylsulphide with Cys111 and restores the monomer–dimer equilibrium of A4V SOD1 to wild-type. Ebselen is therefore a potent bifunctional pharmacological chaperone for SOD1 that combines properties of the SOD1 chaperone hCCS and the recently licenced antioxidant drug, edaravone.

Date: 2018
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-018-04114-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-04114-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-04114-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-04114-x